Solventum Corporation
- Open
- 93.54
- Day high
- 94.12
- Day low
- 92.08
- Prev close
- 91.90
- Volume
- 38K
- Mkt cap
- $15.7B
- P/E (TTM)
- 11.2
- EPS (TTM)
- $8.22
- P/B
- 3.3
- P/S
- 1.9
- Yield
- —
- Per share
- —
Solventum Corporation (SOLV) is a Healthcare company listed on NYSE. The stock is up 30% over the past year. Drillr has 1 published research article covering SOLV.
Solventum Corporation (SOLV) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 7 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
SOLV earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 5, 2026 | $1.90 | $2.55 | +34.2% | $2.2B | +2.6% |
| May 5, 2026 | $1.35 | $1.48 | +9.6% | $2.0B | +2.0% |
| Nov 6, 2025 | $1.43 | $1.50 | +4.9% | $2.1B | +2.0% |
| Aug 7, 2025 | $1.45 | $1.69 | +16.6% | $2.2B | +2.0% |
| May 8, 2025 | $1.21 | $1.34 | +10.7% | $2.1B | +2.7% |
| Feb 27, 2025 | $1.31 | $1.41 | +7.6% | $2.1B | +1.1% |
| Nov 7, 2024 | $1.39 | $1.64 | +18.0% | $2.1B | +1.2% |
| Aug 8, 2024 | $1.51 | $1.56 | +3.3% | $2.1B | +1.6% |
| May 9, 2024 | $1.75 | $2.08 | +18.9% | $2.0B | +2.5% |
| Dec 30, 2023 | — | $0.42 | — | $2.1B | — |
SOLV insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 18, 2026 | Zieselman Neil Craigofficer: SVP, Controller & CAO | Grant | 6,911 | — |
| May 18, 2026 | ALBAN CARLOSdirector | Grant | 3,300 | — |
| May 18, 2026 | COX CARRIE SMITHdirector | Grant | 4,848 | — |
| May 18, 2026 | DeVore Susan D.director | Grant | 3,300 | — |
| May 18, 2026 | Wilson Darryl L.director | Grant | 3,300 | — |
| May 18, 2026 | Wendell Amy McBridedirector | Grant | 3,300 | — |
| May 18, 2026 | WEILAND JOHN Hdirector | Grant | 3,300 | — |
| May 18, 2026 | Mily Elizabethdirector | Grant | 3,300 | — |
| May 18, 2026 | MAY KAREN Jdirector | Grant | 3,300 | — |
| May 18, 2026 | Harris Bernard A Jrdirector | Grant | 3,300 | — |
| May 18, 2026 | Edwards Shirley Anndirector | Grant | 3,300 | — |
| May 18, 2026 | EISENBERG GLENN Adirector | Grant | 3,300 | — |
| May 15, 2026 | Landucci Amyofficer: Chief Information Officer | Tax | 2,017 | $74.41 |
| May 15, 2026 | McMillan Wayde D.officer: Chief Financial Officer | Option | 9,503 | — |
| May 15, 2026 | McMillan Wayde D.officer: Chief Financial Officer | Tax | 4,404 | $74.41 |
Source: SOLV SEC Form 4 filings, latest Aug 18, 2026. For informational purposes only — not investment advice.
See the full SOLV insider & 13F page →Solventum Corporation company profile
Overview
Solventum Corporation (NYSE:SOLV) is a healthcare company that was spun off from 3M Company in April 2024, making it one of the newest publicly traded companies in the medical technology sector. The company was incorporated in 2023 as part of 3M's strategic decision to separate its healthcare business, allowing it to operate as an independent entity focused exclusively on medical solutions. Headquartered in Saint Paul, Minnesota, Solventum has inherited decades of healthcare innovation and manufacturing expertise from its former parent company. The company is currently undergoing a comprehensive three-phase transformation strategy to establish its independent identity, optimize its operations, and position itself for long-term growth in the global healthcare market.
Business
Solventum operates in the medical technology industry, developing, manufacturing, and commercializing healthcare solutions across four distinct business segments. The healthcare technology sector encompasses companies that create medical devices, software systems, and specialized products used by healthcare providers, patients, and related industries. The company's business is organized into four primary segments: 1. **MedSurg** (approximately 58% of revenue): This is Solventum's largest segment, providing critical medical solutions including advanced wound care products such as the V.A.C. (Vacuum Assisted Closure) therapy systems that use negative pressure to promote wound healing, infection prevention products including sterilization indicators and surgical prep solutions, temperature management systems for patient warming and cooling during medical procedures, and surgical supplies including medical electrodes and stethoscopes. These products are essential tools used in hospitals, surgical centers, and clinical settings worldwide. 2. **Dental Solutions** (approximately 16% of revenue): This segment offers a comprehensive portfolio of dental and orthodontic products including orthodontic brackets and aligners used to straighten teeth, restorative cements and bonding agents that dentists use to attach crowns, fillings, and other dental work, and specialized dental materials. The segment serves both general dentists and orthodontic specialists. 3. **Health Information Systems** (approximately 16% of revenue): This technology-focused segment provides software solutions for healthcare providers, including computer-assisted physician documentation systems that help doctors record patient information more efficiently, revenue cycle management software that handles billing and coding for medical procedures, speech recognition technology for medical transcription, and data visualization platforms. These systems help healthcare organizations improve efficiency and reduce administrative burden. 4. **Purification and Filtration** (approximately 10% of revenue): This segment manufactures filtration technologies including specialized filters, purifiers, cartridges, and membranes used in various applications from bioprocessing in pharmaceutical manufacturing to water treatment systems. Note that this segment was divested to Thermo Fisher Scientific in 2024 as part of the company's portfolio optimization strategy.
Revenue model
Solventum generates revenue primarily through direct product sales to healthcare providers, distributors, and end-users across its four business segments. The company operates a traditional manufacturing and distribution business model where it develops, produces, and sells physical medical products and software solutions. The company's primary customers include hospitals and health systems, dental practices and orthodontic clinics, healthcare technology companies, and pharmaceutical manufacturers. Revenue is generated through one-time product sales, recurring purchases of consumable items (such as wound dressings and dental materials), and software licensing agreements for its Health Information Systems products. Several factors influence Solventum's profitability and margins. Positive margin drivers include the company's focus on high-value, specialized medical products that command premium pricing due to their critical nature in healthcare settings, the recurring revenue nature of many consumable products that require regular replacement, and the company's established relationships with major healthcare distributors and providers. The company's innovation pipeline and patent portfolio also provide competitive advantages that support pricing power. Margin pressures come from several sources including healthcare cost containment efforts by hospitals and insurers that create downward pricing pressure, increasing raw material costs and supply chain disruptions, competitive pressures from both established medical device companies and newer entrants, and regulatory compliance costs associated with medical device manufacturing. The company also faces tariff impacts estimated at $80-100 million for 2025, which will pressure margins. Additionally, as a newly independent company, Solventum is experiencing transition costs and operational inefficiencies as it establishes standalone systems and processes separate from its former parent company 3M.
Competitive moat
Solventum's competitive moat is moderate but faces significant challenges as a newly independent company. The company's primary competitive advantages stem from its inherited expertise and established market positions from 3M's healthcare division, including strong brand recognition in critical medical specialties, extensive patent portfolios particularly in wound care and dental materials, and established relationships with major healthcare distributors and providers. The company's strongest moat elements include its specialized knowledge in advanced wound care where products like V.A.C. therapy systems require significant clinical validation and regulatory approval, creating barriers to entry. The dental segment benefits from established relationships with dental professionals and orthodontists who are often slow to switch suppliers due to training requirements and patient continuity concerns. The Health Information Systems segment has some switching costs as healthcare providers invest time and resources in implementing and training staff on these software solutions. However, Solventum's moat faces considerable vulnerabilities. As a newly spun-off entity, the company is experiencing organizational disruption with 80% of its leadership team being new, potentially affecting execution and customer relationships. The medical device industry is highly competitive with well-established players like Johnson & Johnson, Medtronic, and Abbott having deeper resources and broader product portfolios. Additionally, the company operates in mature markets with limited organic growth potential, as evidenced by its modest 1-2% growth guidance. Competitive threats include larger medical device companies that can leverage economies of scale and cross-selling opportunities, emerging digital health companies that may disrupt traditional medical device markets, and private equity-backed competitors that can compete aggressively on pricing. The company's portfolio optimization strategy, including the divestiture of the Purification and Filtration segment, suggests management recognizes that some business areas lack sustainable competitive advantages.
Risks & safety
Solventum presents moderate financial risk with some concerning leverage metrics but adequate liquidity for near-term operations. **Liquidity and Solvency:** - Cash and short-term investments: $534 million as of Q1 2025 - Current ratio: 1.19, indicating tight but adequate short-term liquidity - Free cash flow turned negative at -$80 million in Q1 2025, down from positive $92 million in Q4 2024 - Debt-to-equity ratio of 2.43 indicates high leverage levels **Valuation Metrics:** - EV/EBITDA: 33.9x (Q1 2025) appears elevated for a mature medical device company - P/E ratio: 24.1x based on recent earnings - Price-to-book ratio: 4.0x suggests premium valuation relative to book value - Graham number suggests potential overvaluation at current price levels **Other Considerations:** - High debt burden inherited from 3M spin-off creates financial constraints - Transformation costs and separation expenses pressuring near-term profitability - Tariff headwinds of $80-100 million expected in 2025 - Portfolio divestiture proceeds will help reduce debt burden
Recent development
Since its spin-off from 3M in April 2024, Solventum has embarked on a comprehensive three-phase transformation strategy to establish itself as an independent healthcare company. **Phase 1** focused on foundational elements including leadership restructuring (with 80% of the leadership team being new), establishing the company's mission and values, and managing the complex separation from 3M including ERP system implementations across multiple countries. The company also launched the "Solventum Way" restructuring program to create a more agile organization. **Phase 2** centers on strategic planning and identifying growth drivers, with management developing a long-range plan that was unveiled at an Investor Day in March 2025. The company has identified five key growth driver areas and is focusing on commercial excellence, R&D innovation, and potential strategic acquisitions. Key product launches during this period include the V.A.C. Peel and Place dressing in the MedSurg segment, Clinpro Clear Fluoride Treatment in Dental Solutions, and AI-driven autonomous coding technology in Health Information Systems. **Phase 3** involves portfolio optimization, most notably the divestiture of the Purification and Filtration business to Thermo Fisher Scientific. This strategic move allows Solventum to focus resources on its core healthcare segments while using divestiture proceeds primarily for debt reduction. The company has also undertaken significant SKU rationalization, identifying 3,500 SKUs (5% of total) for elimination to streamline operations. Throughout this transformation, Solventum has maintained focus on operational improvements including talent acquisition, commercial structure changes to improve accountability, and addressing innovation gaps in key segments. The company has demonstrated three consecutive quarters of volume growth and raised its organic growth guidance from flat-to-1% to 1.5%-2.5% for 2025, indicating improving operational momentum despite the challenges of operating as a newly independent entity.
SOLV company profile · for informational purposes only — not investment advice.
Track SOLV with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free